Group 1 - U.S. stocks experienced an upward trend, with the Dow Jones increasing by approximately 200 points on Thursday [1] - Eagle Bancorp, Inc. reported fourth-quarter earnings of 25 cents per share, surpassing the analyst consensus estimate of a loss of 10 cents per share [1] - The company's quarterly sales reached $68.303 million, exceeding the analyst consensus estimate of $67.033 million [1] Group 2 - Eagle Bancorp shares surged by 19.8% to $28.80 on Thursday [2] - Rich Sparkle Holdings Limited saw a significant increase of 44.7% to $99.96 [3] - Regencell Bioscience Holdings Limited's shares rose by 37.6% to $30.15 [3] - New Era Energy & Digital, Inc. experienced a rise of 31.6% to $9.02 [3] - Corcept Therapeutics Incorporated climbed 17.6% to $42.70 following positive Phase 3 trial results [3] - USA Rare Earth, Inc. gained 17.5% to $22.72 [3] - LSI Industries Inc. rose 15.7% to $23.59 after reporting strong quarterly earnings [3] - NVE Corporation's shares increased by 15.7% to $79.20 following third-quarter results [3] - Sasol Limited's shares jumped 12.7% to $7.11 after raising its six-month performance fuel sales guidance for FY25 [3] - Terrestrial Energy Inc. rose 12.1% to $11.93 [3] - Arista Networks, Inc. gained 10.6% to $140.86 [3] - GRAIL, Inc. saw an increase of 10% to $111.20 [3] - Lemonade, Inc. shares jumped 8.4% to $92.55 [3] - Iridium Communications Inc. gained 8% to $21.19 [3] - Moderna, Inc. increased by 7.3% to $53.43 [3] - Alibaba Group Holding Limited rose 6.6% to $179.81 amid reports of moving towards an IPO for its AI chipmaking unit [3] - Datadog, Inc. shares rose 5.9% to $130.79 after an upgrade from Stifel [3]

Core Points - The conference call is focused on the positive 9-month update from Immuneering's ongoing Phase IIa trial of atebemetinib in first-line pancreatic cancer patients [1] - Key executives from Immuneering, including the CEO and Chief Scientific Officer, are present on the call to discuss the trial results and future plans [2] Company Updates - Immuneering is currently conducting a Phase IIa trial for atebemetinib, which is aimed at treating first-line pancreatic cancer patients [1][3] - The management team is expected to provide forward-looking statements regarding the trial and the timing of additional data [3][4]